Abstract
More than a century after the identification of Toxoplasma gondii, major issues need to be addressed for the optimal management of ocular disease. Toxoplasmic retinochoroiditis is the main cause of posterior uveitis in several geographical areas. The parasite establishes a love–hate relationship with the eye, manipulating the immune response and inducing variable initial lesions and further relapses. It is now well established that most cases are acquired after birth and not congenital. The severity of the disease is mainly due to the parasite genotype and the host immune status. Diagnosis is based on clinical features, but may be confirmed by biological tools applied to ocular fluids. Combining several techniques improves the diagnostic yield in equivocal cases. Therapeutic management is the most important challenge. Even though evidence-based data on the efficacy of anti-parasitic drugs are still missing, new strategies with a good safety profile are available and may be proposed earlier during the course of the disease, but also in selected cases, to reduce sight-threatening relapses. Revisiting the therapeutic options and indications may be an important step towards long-term maintenance of the visual function and avoidance of major complications.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Wakefield D, Cunningham Jr ET, Pavesio C, Garweg JG, Zierhut M . Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19 (1): 2–9.
Nicolle C, Manceaux L . Sur une infection à corps de Leishman (ou organismes voisins) du gondi. CR Seances Acad Sci 1908; 147: 763–766.
Nicolle C, Manceaux L . Sur un protozoaire nouveau du gondi. CR Seances Acad Sci 1909; 148: 369–372.
Splendore A . Un nuovo protozoa parassita de’ conigli. incontrato nelle lesioni anatomiche d’une malattia che ricorda in molti punti il Kala-azar dell’ uomo. Nota preliminare pel Rev Soc Scient Sao Paulo 1908; 3: 109–112.
Chatton E, Blanc G . Notes et reflexions sur le toxoplasme et la toxoplasmose du gondi. (Toxoplsma gundii Ch. Nicolle et Manceaux 1909). Arch Inst Pasteur Tunis 1917; 10: 1–41.
Jankû J . Pathogensa a pathologica anatomie T. Zv. vrozaneho kolobou zlute skurney oku normal ne velikem a mikrophtalmickem s nalezem parisitu v sitnici. Cas Lek Ses 1923; 62: 1021–1027.
Wolf A, Cowen D, Paige B . Human toxoplasmosis: occurence in infants as an encephalomyelitis; verification by transmission to animals. Science 1939; 86: 226–227.
Dubey JP . History of the discovery of the life cycle of Toxoplasma gondii. Int J Parasitol 2009; 39 (8): 877–882.
Commodaro AG, Belfort RN, Rizzo LV, Muccioli C, Silveira C, Burnier Jr MN et al. Ocular toxoplasmosis: an update and review of the literature. Mem Inst Oswaldo Cruz 2009; 104 (2): 345–350.
Talabani H, Mergey T, Yera H, Delair E, Brezin AP, Langsley G et al. Factors of occurrence of ocular toxoplasmosis. A review. Parasite 2010; 17 (3): 177–182.
Vallochi AL, Goldberg AC, Falcai A, Ramasawmy R, Kalil J, Silveira C et al. Molecular markers of susceptibility to ocular toxoplasmosis, host and guest behaving badly. Clin Ophthalmol 2008; 2 (4): 837–848.
Vaudaux JD, Muccioli C, James ER, Silveira C, Magargal SL, Jung C et al. Identification of an atypical strain of toxoplasma gondii as the cause of a waterborne outbreak of toxoplasmosis in Santa Isabel do Ivai, Brazil. J Infect Dis 2010; 202 (8): 1226–1233.
Jones JL, Holland GN . Annual burden of ocular toxoplasmosis in the US. Am J Trop Med Hyg 2010; 82 (3): 464–465.
Garweg JG, Scherrer JN, Halberstadt M . Recurrence characteristics in European patients with ocular toxoplasmosis. Br J Ophthalmol 2008; 92 (9): 1253–1256.
Holland GN . Ocular toxoplasmosis: the influence of patient age. Mem Inst Oswaldo Cruz 2009; 104 (2): 351–357.
Holland GN, Crespi CM, ten Dam-van Loon N, Charonis AC, Yu F, Bosch-Driessen LH et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 2008; 145 (6): 1007–1013.
Fekkar A, Ajzenberg D, Bodaghi B, Touafek F, Le Hoang P, Delmas J et al. Direct genotyping of Toxoplasma gondii in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type II in France. J Clin Microbiol 2011; 49 (4): 1513–1517.
Gilbert RE, See SE, Jones LV, Stanford MS . Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2002; (1): CD002218.
Stanford MR, Gilbert RE . Treating ocular toxoplasmosis: current evidence. Mem Inst Oswaldo Cruz 2009; 104 (2): 312–315.
Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011; 118 (1): 134–141.
Silveira C, Belfort Jr R, Muccioli C, Holland GN, Victora CG, Horta BL et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 2002; 134 (1): 41–46.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Bodaghi, B., Touitou, V., Fardeau, C. et al. Toxoplasmosis: new challenges for an old disease. Eye 26, 241–244 (2012). https://doi.org/10.1038/eye.2011.331
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.331
